BioSig Technologies, Inc. is providing an update since the launch of BioSig?s established technology team with external partners and collaborators to advance the research and development of an artificial intelligence (?AI?) medical device platform. On July 20, 2023, the company announced the inclusion of BioSig AI Sciences, Inc., a majority owned subsidiary of the Company (?BAIS?), in Nvidia?s Inception partnership program, providing the team access to engineering and technology support. On July 23, 2023, BAIS completed its seed round of funding of $2.2 million.

The funding valued the majority owned subsidiary at $15 million. In less than a month since closing BAIS?s initial funding, it has been meeting with numerous hospital customers at the levels of leadership. BAIS has identified numerous opportunities to bring proprietary AI platform to market.

In addition, BAIS has recently signed a collaboration agreement with a leading global technology organization who will be building important data infrastructure, enabling a scaling of the platform in high-volume, data intensive hospital centers.